Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

被引：5
|
作者：
Le, Xiuning
Goldman, Jonathan Wade
Clarke, Jeffrey Melson
Tchekmedyian, Nishan
Piotrowska, Zofia
Chu, David
Bhat, Gajanan
Lebel, Francois M.
Socinski, Mark A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[3] Duke Canc Inst, Durham, NC USA
[4] Pacific Shores Med Grp, Long Beach, CA USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[6] North Shore Hematol Oncol Associates, East Setauket, NY USA
[7] Spectrum Pharmaceut, Irvine, CA USA
[8] AdventHlth Canc Inst, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9514
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Elamin, Yasir Y.
    Robichaux, Jacqulyne P.
    Carter, Brett W.
    Altan, Mehmet
    Tran, Hai
    Gibbons, Don L.
    Heeke, Simon
    Fossella, Frank, V
    Lam, Vincent K.
    Le, Xiuning
    Negrao, Marcelo, V
    Nilsson, Monique B.
    Patel, Anisha
    Vijayan, R. S. K.
    Cross, Jason B.
    Zhang, Jianjun
    Byers, Lauren A.
    Lu, Charles
    Cascone, Tina
    Feng, Lei
    Luthra, Rajyalakshmi
    San Lucas, Francis A.
    Mantha, Geeta
    Routbort, Mark
    Blumenschein, George, Jr.
    Tsao, Anne S.
    Heymach, John, V
    CANCER CELL, 2022, 40 (07) : 754 - +
  • [22] Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
    Riess, Jonathan
    Floch, Nicolas
    Martin, Matthew
    Orme, Jonathon
    Staniszewska, Anna
    Menard, Ludovic
    Cuomo, Maria Emanuela
    O'Neill, Daniel
    Ward, Richard
    Finlay, Raymond
    McKerrecher, Darren
    Cheng, Mingshan
    Tang, Daniel
    Tsai, Rebekah
    Ye, Chunting
    Keck, James G.
    Gandara, David R.
    Mack, Philip C.
    Cross, Darren
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
    Janne, Pasi A.
    Neal, Joel W.
    Camidge, D. R.
    Spira, Alexander
    Piotrowska, Zofia
    Horn, Leora
    Costa, Daniel B.
    Tsao, Anne
    Patel, Jyoti
    Gadgeel, Shirish
    Bazhenova, Lyudmila
    Zhu, Viola W.
    West, Howard
    Vincent, Sylvie
    Zhu, Jian
    Li, Shuanglian
    Riely, Gregory J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study
    Popat, Sanjay
    Ramalingam, Suresh
    Zhou, Caicun
    Kim, Tae
    Yang, James
    Riely, Gregory
    Mekhail, Tarek
    Nguyen, Danny
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Misch, Daniel
    Kaur, Manmit
    Bunn, Veronica
    Lin, Huamao
    Zhang, Pingkuan
    Janne, Pasi
    LUNG CANCER, 2023, 178 : S35 - S35
  • [25] EGFR testing patterns and detection of EGFR exon 20 insertions among patients with NSCLC in the US
    Lin, H. M.
    Yin, Y.
    Curran, E.
    Crossland, V.
    Wu, Y.
    Ou, S.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 : S142 - S143
  • [26] Molecular characteristics of EGFR exon 20 uncommon R776H mutation and response to osimertinib in NSCLC patients.
    An, Gaili
    He, Li
    Wang, Xifang
    Lei, Yu
    Gu, Dejian
    Chen, Rongrong
    Xia, Xuefeng
    Bai, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
    Lund-Iversen, Marius
    Kleinberg, Lilach
    Fjellbirkeland, Lars
    Helland, Aslaug
    Brustugun, Odd Terje
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1471 - 1473
  • [28] Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
    Janne, Pasi A.
    Neal, Joel W.
    Camidge, D. Ross
    Spira, Alexander I.
    Piotrowska, Zofia
    Horn, Leora
    Costa, Daniel Botelho
    Tsao, Anne S.
    Patel, Jyoti D.
    Gadgeel, Shirish M.
    Bazhenova, Lyudmila
    Zhu, Viola Weijia
    West, Howard
    Vincent, Sylvie
    Zhu, Jian
    Li, Shuanglian
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
    Heymach, J.
    Negrao, M.
    Robichaux, J.
    Carter, B.
    Patel, A.
    Altan, M.
    Gibbons, D.
    Fossella, F.
    Simon, G.
    Lam, V.
    Blumenschein, G.
    Tsao, A.
    Kurie, J.
    Mott, F.
    Jenkins, D.
    Mack, D.
    Feng, L.
    Roeck, B.
    Yang, Z.
    Papadimitrakopoulou, V.
    Elamin, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S323 - S324
  • [30] Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation
    Basse, Clemence
    Blancard, Lucie Regaldo-Saint
    BULLETIN DU CANCER, 2023, 110 (09)
12345